Rationale: to investigate the role of 68Ga-DOTA-NOC SUVmax as a potential prognostic factor in patients with pancreatic neuroendocrine tumour (pNET).
INTRODUCTION
Pancreatic neuroendocrine neoplasms (pNET, WHO 2010) are considered a rare pathology with a wide spectrum of clinical presentations. Their real incidence is quite controversial: although they are found in about 1% of autopsies, their clinical incidence is reported to be only about 0.5 -1/100,000 (1, 2) .
Although pNET are characterized by an overall better prognosis as compared to other forms of solid tumours, the patient outcome can vary greatly depending on the tumour grading (3) and disease extent (4) . However, the improved diagnostic and therapeutic management of these patients has led to an increase in the prevalence of the disease and, in turn, atypical presenting cases have increased, showing heterogeneous clinical behaviour, either at diagnosis or during the course of the disease. Therefore, the possibility to identify prognostic parameters that may help the clinicians to stratify patients in different risk groups is extremely relevant.
The diagnostic flow-chart of pNET currently includes several imaging modalities both morphological (US, CT, MRI) and functional (somatostatin receptors scintigraphy, PET/CT with 68Ga-DOTApeptides) (5-7). In the past five years, PET/CT with 68Ga-DOTA-peptides has been increasingly employed for the high accuracy in lesions detection (at both the primary and metastatic sites), safety, contained costs (5-7) and for selecting patients to be addressed to Peptide Receptor Radionuclide All patients gave their written informed consent to participate in the study. The study protocol was approved by our local Ethical Committee of the S.Orsola-Malpighi Hospital and was performed according to the Helsinki Declaration for human studies.
PET/CT with 68Ga-DOTA-NOC was performed following current international guidelines (intravenous injection of 120-185MBq followed by an uptake time of 60 min (range 45-90), without specific exam preparation) (14) . 68Ga-DOTANOC was synthesized by the Radiopharmacy of the Nuclear Medicine Unit of S.Orsola-Malpighi Hospital. 68Ga was eluted from a 68Ge/68Ga generator, and DOTANOC was labelled with 68Ga following the procedure described by Zhernosekov et al. (15) . 68Ga-DOTANOC PET scans were obtained using a dedicated PET/CT scanner (Discovery LS; GE Healthcare). PET emission images were recorded for 4 min per bed position; CT images were used for non-uniform attenuation correction (acquisition parameters, 140 kV, 90 mA, 0.8 s; tube rotation, 5-mm thickness). All images were corrected for scatter, randoms, dead time, and decay. Images were reconstructed with a 2-dimensional ordered-subset expectation maximization iterative algorithm (2 iterations, 28 subsets).
PET/CT images were acquired from the skull base to the middle of the thigh. PET/CT results were evaluated by two skilled nuclear medicine specialists unaware of the results of the other imaging modalities and the definitive report was reached by consensus. Any localization with an intensity greater than background that could not be explained by physiologic activity (pituitary gland, spleen, liver, adrenals, kidneys, and urinary bladder) was considered to be indicative of somatostatin receptors expression. Progression-free survival (PFS) was defined as the interval between 68Ga-DOTANOC PET/CT and the time of progression of disease (PD). PFS was measured using the Kaplan-Meier method, and the results were compared using the log-rank test. Analysis of the predictive risk factors for PD was carried out by univariate and multivariate analysis using the Cox proportional hazards method. Risk factors were expressed as hazard ratios (HR) [95 % confidence interval (CI)]. The multivariate model was constructed using the forward stepwise method after including all variables. All analyses carried out for risk factors are listed in the tables.
The p value was considered significant when less than 0.05. The statistical analysis was carried out using dedicated software (SPSS version 19.0, SPSS Inc.).
To evaluate the potential role of SUVmax on prognosis, we divided the patients on the basis of the disease status (PD vs stable disease, SD) at an arbitrary selected time-point follow-up. A 24 months time-point follow-up was chosen considering that about half of our patients underwent PRRT, that PFS in patients treated with PRRT was reported to be 23 months in the pancreatic subgroup of a recent multicenter trial (18) and that our follow-up schedule included a radiological evaluation at 24 months (CT scan every 3 months during the first year and every 6 months afterwards).
RESULTS

Patient Characteristics
Overall 43 patients (22 men and 21 women; median age 58 years; IQR 48-64 years) with pNET were included in the study. Eight patients (18.6%) had functioning tumours: 5 gastrinomas, one insulinoma, one VIPoma and one ACTH-oma. In the remaining 35 (81.4%) the tumour was non-functioning.
According to the 2010 WHO classification, 14 patients (32.3%) had a NET G1, 29 (67.7%) had a NET G2.
The median Ki67 index was 6.1% (IQR, 2.0%-8.9%); 22 of 43 patients (51.2%) had a Ki67 of 5% or less, and 21 of 43 patients (48.8%) had a Ki67 greater than 5%.
According to the TNM classification, 7 patients (16.3%) had stage IIIB disease, 36 (83.7%) had stage IV.
The characteristics of all 43 patients are listed in Table 1 To evaluate the potential role of SUVmax on prognosis, we divided the patients on the basis of the disease status (PD vs SD) at 24 months follow-up. As reported in Table 1 , our data showed that SUVmax was significantly higher (p=0.022) in patients with SD ( Figure 1 Figure 2 ). Five patients were not included in the analyses since they presented stable disease and had a follow-up inferior to 24months.
The receiver-operating-characteristic curve of the SUVmax in predicting patients who had PD after 24 month of follow-up was quite accurate (area under the curve±SE=0.715±0.084; p=0.023), and the best cut-off ranged from 37.8 to 38.0. The sensitivity and specificity obtained using the best cut-off values were 72.2% and 70.0% respectively.
Predictors for tumour progression
At univariate analysis, the variables considered as risk factors for tumour progression are summarized in Table 2 . Risk factors for tumour progression at univariate analysis were: SUVmax ≤ 37.8 (HR 3.09, p=0.003), medical therapy alone (HR 2.36, p=0.0148) and Ki67>5% (HR 2.89, p=0.009). Ki67 >5% (HR 3.24), stage IV (HR 3.31), medical therapy alone (HR 2.70) and SUVmax ≤ 37.8 (HR 2.37) were risk factors for tumour progression at multivariate analysis.
Progression-free Survival
Overall, median PFS was 23 months (Figure 3 ). Significant differences in PFS were observed in relationship to Ki67 (median: 45 months for Ki67≤5%; 20 months for ki67>5%; p=0.005; Figure 3A 
DISCUSSION
In the past decade, both the optimization of the diagnostic algorithms (especially after the advent of 68Ga-DOTA-peptides PET/CT) and the employment of novel therapeutic strategies (mainly PRRT and novel biologic target drugs), determined an increase in NET prevalence. Correspondingly, clinicians witnessed an increment of atypical cases that do not fit in the classical paradigm of NET always being indolent tumours. Therefore, the identification of easily assessable prognostic parameters is crucial, for both an accurate evaluation at baseline and during the course of the disease, since an initially indolent tumour may turn into a more aggressive behaviour. SUVmax is an optimal parameter since it can be easily assessed in a relatively non-invasive way. Moreover, being PET/CT a whole-body procedure, it provides a functional evaluation of the whole tumour burden, that is not feasible with the commonly used Ki67.
A wide literature on 68Ga-DOTA-peptides PET/CT imaging is focused on assessing the diagnostic accuracy (5,7) and the performance of one tracer over the other (19, 20) .
To our knowledge, on the contrary to 18F-FDG (21, 22) , the potential prognostic role of 68Ga-DOTApeptides SUVmax has been scarcely investigated. Two recent papers reported how the 68Ga-DOTA-NOC SUVmax correlates with somatostatin receptors expression (9,23) and two previous studies investigated the potential prognostic role of SUVmax in patients with neuroendocrine tumours with different primary sites (9, 10) . However, pNET generally show a more aggressive clinical behaviour as compared to other forms of NET (8,11), with 5-years survival rates ranging between 25 and 75% (24) (25) (26) . Therefore, the identification of specific prognostic factors assessed in an homogeneous population of NET patients with pancreatic primary is mandatory.
In view of these clinical needs, the population under study included only patients with pancreatic primary, with a long follow-up (median 20 months), while MEN cases (a condition known to present a different clinical behaviour) were excluded.
Our study showed that SUVmax may be used to predict outcome in pNET patients. In particular, a higher SUVmax was associated with a better outcome. The best cut-off to discriminate between patients with stable disease/partial response from those with progressive disease ranged between 37.8 -38.0. This value is higher than the ones reported in both previous studies, including patients with different primary sites (19.3 and 14.5, respectively) (9, 10) . This may be partly explained by the documented higher SUVmax values of the pancreatic primary tumours (9) . A previous report by O'Toole et al. (27) observed higher level of SSTR2 and SSTR5 mRNA in patients with pancreatic NET as compared to neuroendocrine tumours with other primary.
To our knowledge this is the first report of the role of SUVmax in predicting progression-free survival in pNET. Several recent reports analysed the role of different prognostic factors in terms of progression free survival. In particular, Panzuto et al described the role of poorly differentiated tumours, Ki67>5% and no treatment after diagnosis, as risk factors for disease progression at multivariate analysis (8). In line with such results, our data support the employment of a Ki67 cut-off value of 5% for differentiating patients that will present a more aggressive behaviour from the ones with a more indolent disease (as opposed to the widely accepted cut-off of 2%, that is used for NET with other primary sites) (8).
Recently, much attention has being focused on the potential role of double tracer imaging (68Ga-DOTA-peptides/18F-FDG) for a complete biological characterization of the disease, since a worst (18) on radiolabelled somatostatin analogue treatment. Acknowledging the inherent problems of inter-study comparisons, the reported effect of PRRT in terms of progression free survival (18, (32) (33) (34) seems to be superior than chemotherapy (median PFS less than 18 months) (35, 36) or targeted therapies, such as sunitinib (11.4 months) (37) and everolimus (11.0 months) (38) .
The results reported in this paper are therefore supporting the role of PRRT in the therapeutic management of pNET patients and underline the need to standardise regimens over different centers and countries. In fact, only practical guidance signed by the IAEA, EANM, and SNMMI is currently available for PRRT (31). 
